Provided is a method for resolution of formula 4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxy-methyl benzonitrile as an enantiomer thereof, comprising the following steps: a salt of (S)-4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxymethyl benzonitrile with a resolving agent D-(+)di-p-toluoyl tartaric acid was crystallized in a resolving solvent; the method is characterized in that the resolving solvent is an ether solvent. Also provided is a new crystal form of the resolved intermediate.

Provided is a method for resolution of formula 4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxy-methyl benzonitrile as an enantiomer thereof, comprising the following steps: a salt of (S)-4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxymethyl benzonitrile with a resolving agent D-(+)di-p-toluoyl tartaric acid was crystallized in a resolving solvent; the method is characterized in that the resolving solvent is an ether solvent. Also provided is a new crystal form of the resolved intermediate.

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (I): ##STR00001##
wherein X is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, or substituted heteroalkenyl.

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (I): ##STR00001##
wherein X is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, or substituted heteroalkenyl.

An azo compound excellent in solubility in solvent and having a high absorbance coefficient is disclosed, as well as an ink containing the azo compound. Such an ink contains a solvent having a relative permittivity at 22° C. and at a measurement frequency of 1 kHz of 3 or less and having a solubility in water at 25° C. of 20 mg/L or less, and an azo compound.

An azo compound excellent in solubility in solvent and having a high absorbance coefficient is disclosed, as well as an ink containing the azo compound. Such an ink contains a solvent having a relative permittivity at 22° C. and at a measurement frequency of 1 kHz of 3 or less and having a solubility in water at 25° C. of 20 mg/L or less, and an azo compound.

The present invention provides to an improved process for the preparation of highly pure Erlotinib hydrochloride of formula (I)

##STR00001##

The substantially pure Erlotinib hydrochloride (I) obtained by improved process of the present invention is having purity of greater than 99.8% (% w/w by HPLC).
Erlotinib hydrochloride is useful in the treatment of cancer more particularly in the treatment of lung cancer and pancreatic cancer.

The present invention provides to an improved process for the preparation of highly pure Erlotinib hydrochloride of formula (I)

##STR00001##

The substantially pure Erlotinib hydrochloride (I) obtained by improved process of the present invention is having purity of greater than 99.8% (% w/w by HPLC).
Erlotinib hydrochloride is useful in the treatment of cancer more particularly in the treatment of lung cancer and pancreatic cancer.

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.